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Abstract
Objective and design This systematic review aims to establish the role of CD8 + T lymphocytes in COPD.
Methods Forty-eight papers published in the last 15 years were identified for inclusion.
Results CD8 + T-cells are increased in the lungs of patients with COPD (17 studies, 16 positive) whereas in the circula-
tion, findings were inconclusive. Activation of CD8 + T-cells was enhanced in lungs (four studies, three positive) but cell 
phenotype was unclear. There was substantial evidence of a higher proportion of type 1 CD8 + (Tc1) cells in COPD (11 
studies, 9 positive), though the population of type 2 (Tc2) cells was also increased (5 studies, 4 positive). CD8 + T-cells in 
COPD exhibited greater expression of cytotoxic proteins (five studies, five positive). Studies assessed a variety of questions 
so evidence was insufficient to draw firm conclusions. The role of CD8 + T-cells at acute exacerbation of COPD and also 
their contribution to alveolar destruction can only be hypothesised at this stage.
Conclusions Not only is the number of CD8 + T-cells increased in COPD, these cells have increased capacity to exert effec-
tor functions and are likely to contribute to disease pathogenesis. Several mechanisms highlighted show promise for future 
investigation to consolidate current knowledge.
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Introduction
COPD (chronic obstructive pulmonary disease) is a treatable 
and preventable disease state, characterized by progressive 
airflow limitation that is not fully reversible. It is a current 
and growing cause of mortality and morbidity worldwide. 
The pathological hallmarks of COPD are destruction of the 
lung parenchyma (pulmonary emphysema), inflammation 
of the central airways (chronic bronchitis) and inflamma-
tion of the peripheral airways (respiratory bronchiolitis). 
The destructive changes and tissue remodelling observed 
in COPD are a result of complex interactions between cells 
of the innate and adaptive immune systems, with growing 
interest in the role of CD8 + T lymphocytes.
By collating the current evidence, this systematic review 
aims to determine the exact role that CD8 + T lymphocytes 
have in the pathogenesis of COPD. Since the burden of 
COPD is increasing, a better understanding of the underly-
ing pathology could help to identify new therapeutic targets.
Methods
Search strategy
All searches were carried out in October 2019. PubMed and 
Embase were the two databases chosen for this systematic 
review. Controlled vocabulary was included following a 
search of the MeSH and Emtree databases, respectively.
The search strategy for PubMed was as follows:
(((T-lymphocytes, Cytotoxic [MeSH Terms]) OR CD8-
positive T-lymphocytes [MeSH Terms])) AND (((((pul-
monary disease, chronic obstructive [MeSH Terms]) OR 
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pulmonary emphysema [MeSH Terms]) OR chronic bron-
chitis [MeSH Terms]) OR COPD [Title/Abstract]) OR 
chronic obstructive pulmonary disease [Title/Abstract]) 181 
papers were identified as a result of this search.
The search strategy for Embase was as follows:
(exp chronic obstructive lung disease/OR exp lung 
emphysema/OR exp chronic bronchitis/OR chronic obstruc-
tive pulmonary disease.ab. OR chronic obstructive pulmo-
nary disease.ti. OR COPD.ab. OR COPD.ti.) AND (exp 
cytotoxic T lymphocyte/ OR exp CD8 + T lymphocyte/).
617 papers were identified as a result of this search.
Inclusion of publications
The database searches revealed a total of 798 papers which 
was reduced further to 710 following removal of duplicates. 
Title and abstract screening of the remaining papers was 
conducted using Rayyan systematic review scanner soft-
ware. Common reasons for exclusion included publications 
which did not consider COPD or CD8 + T lymphocytes spe-
cifically and those of the wrong publication type, such as 
review articles. Further to this, papers written in a foreign 
language were excluded due to the potential loss of meaning 
in translation. The decision to place a time restriction to the 
last 15 years (2005 onwards) was made to only include the 
most topical research. Consequently, 51 papers were identi-
fied for full text analysis.
Three publications were excluded during full text analy-
sis, of which two were conference abstracts whereas one was 
not in English. A final total of 48 papers were included in 
the study. The PRISMA 2009 flow chart of article selection 
is shown in Fig. 1.
Further details of the search strategy and inclusion/exclu-
sion criteria for this systematic review are given in Online 
Resource 1. Following full text screening, 48 papers were 
identified for inclusion.
Results
Presence of CD8 + T lymphocytes in COPD
Ten studies analysed the presence of CD8 + T lymphocytes 
in patients with COPD [1–10], nine of which noted a signifi-
cant association (further details are given in Online Resource 
2). Eight studies examined cells in lung samples, with four 
Fig. 1  PRISMA 2009 flow 
diagram showing the screening 
process and the inclusion of 
studies
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of these also examining cell numbers in peripheral blood, 
and two studies examined cells in peripheral blood alone. All 
included human patients with COPD and both non-COPD 
smokers (S) and healthy non-smokers (HNS) were included 
in eight of the studies, whilst one had no control and another 
included asthmatics and non-smokers as comparators.
Of the four studies which sampled lung tissue [1–3, 8], all 
used immunohistochemistry to show increased quantities of 
CD8 + T lymphocytes in COPD. Analysis of BAL was car-
ried out in three studies [7, 9, 10], one of which also sampled 
induced sputum [9]. Like the above studies, evidence for 
increased numbers of CD8 + T lymphocytes in COPD was 
presented in all three. Samples obtained by endobronchial 
biopsy were included in two studies [2, 4]. Löfdahl et al. 
[4] showed a significantly greater number of intraepithelial 
CD8 + T lymphocytes in COPD patients compared to HNS. 
On the other hand, Eapen et al. [2] observed lower numbers 
of CD8 + T lymphocytes in the large airways of smokers 
with and without COPD.
Hodge et  al. [10] performed bronchial brushing and 
reported that the percentage of bronchial mucosal CD8 + T 
lymphocytes was significantly increased in smoker controls 
and also in the group of ex-smokers with COPD taking 
inhaled corticosteroids.
Of the six studies which analysed peripheral blood 
[5–10], three reported no difference in the CD8 + T lym-
phocyte counts between subjects with COPD, S or HNS [6, 
8, 9]. On the contrary, Forsslund et al. [7] reported a lower 
percentage of CD8 + T lymphocytes in the peripheral blood 
of smokers with and without COPD compared to HNS. This 
is contradictory to the findings of Hodge et al. [10] who 
showed an increased percentage of CD8 + T lymphocytes in 
the peripheral blood of both ex-smoking and current smok-
ing patients with COPD in comparison to S and HNS.
Fifteen further studies included findings regarding the 
numbers of CD8 + T lymphocytes in COPD. However, the 
main findings from all 15 studies are described elsewhere 
in this review [11, 15–17, 19, 21, 25, 28–30, 33, 36–39].
Phenotypic analysis of CD8 + T lymphocytes in COPD
Investigation into surface marker expression/phenotype of 
CD8 + T lymphocytes in COPD was conducted in 11 stud-
ies [11–21] (further details are given in Online Resource 3).
CD69, CD25 and HLA-DR are expressed on activated 
CD8 + T lymphocytes. Three studies reported increased 
activation of CD8 + T lymphocytes in COPD lung samples 
[11, 12, 16] and two highlighted a smoking-independent 
activation of CD8 + T lymphocytes in COPD [11, 12]. In 
contrast to the above, a small study [14] reported negligible 
and indifferent CD25 expression on BAL CD8 + T lympho-
cytes in both COPD and controls. Two studies highlighted 
changes in KIR expression of CD8 + T lymphocytes in 
COPD patients and S [12, 16].
Two studies [14, 18] investigated CD103, an integrin 
thought to have co-stimulatory effects on T cell activa-
tion and a role in adhesion. Neither reported a difference 
in CD103 expression on circulating CD8 + T lymphocytes 
between COPD and controls. Glader et al. [14] also found 
no difference in the lungs whereas Mikko et al. [18] noted 
an increase of CD8 + /CD103 + T cells in BAL of current 
smokers with COPD and S compared to HNS.
Seven studies characterised the phenotype of CD8 + T 
lymphocytes in COPD. In the lung, two of five studies 
showed that a higher proportion of CD8 + T lymphocytes 
are of the memory phenotype (CD45RO +) in COPD [14, 
19]. Urbanowicz et al. [19] also highlighted an elevated 
percentage of cytotoxic effector memory (TEMRA) cells 
in induced sputum of COPD patients. Similarly, Barceló 
et al. [13] concluded a final-activation maturation state of 
CD8 + CD45RA + T lymphocytes in the lung following anal-
ysis of BAL. Mikko et al. [18] also reported that intraepi-
thelial CD8 + T lymphocytes were terminally differentiated. 
Conversely, Freeman et al. [20] concluded that CD8 + T 
lymphocytes in lung tissue of COPD patients were short-
term effector memory T cells (CD62L-/CD27-) rather than 
terminally differentiated. Meanwhile in peripheral blood, 
one study [13] found no difference in the proportions of 
naïve and memory CD8 + T lymphocytes between COPD 
and control groups. Koch et al. [17] observed a smoking-
related cytotoxic effector phenotype (CD27-/CD45RA +) on 
CD8 + T lymphocytes in smokers with and without COPD 
compared to HNS whereas Urbanowicz et al. [21] on the 
other hand detected a lower proportion of TEMRA cells in 
COPD and S. Finally, three studies demonstrated increased 
expression of chemokine receptors on CD8 + T lymphocytes 
in COPD [15, 17, 19].
Two studies found that upregulation of the CXCR3 
chemokine receptor on CD8 + T lymphocytes in COPD was 
smoking-independent [17, 19]. This increase was observed 
in both peripheral blood and induced sputum. On the con-
trary, analysis of BAL by Smyth et al. [15] found no dif-
ference in CXCR3 but did find increased expression of 
CCR5 and CCR3 on CD8 + T lymphocytes from the lungs 
of COPD compared to controls.
Inflammatory cytokine profile of CD8 + T 
lymphocytes in COPD
Eleven studies investigated the inflammatory cytokine pro-
file of CD8 + T lymphocytes in COPD [22–32]. One study 
used a mouse model [31] whilst the remaining obtained 
human samples (further details are given in Online Resource 
4).
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Greater production of IFN-g and/or TNF-a by CD8 + T 
lymphocytes from peripheral blood COPD samples was 
shown in five studies [10, 23–26]. As for the lung samples, 
two studies showed enhanced production of Tc1 cytokines 
by CD8 + T lymphocytes obtained from COPD patients 
[10, 32], being higher in smokers than ex-smoker patients. 
Moreover, two studies highlighted the effects of cigarette 
smoke in induction of a Tc1 phenotype [27, 31]. By contrast, 
two studies found no association between the Tc1 profile of 
CD8 + T lymphocytes and COPD [29, 30].
Five studies investigated the Tc2 subpopulation of 
CD8 + T lymphocytes in COPD [23, 25, 26, 29, 30]. Two 
of these studies examined BAL and highlighted an increase 
in Tc2 cytokine expression by CD8 + T lymphocytes in 
COPD [29, 30]. In peripheral blood, two studies highlighted 
a marked increase in Tc2 cells amongst CD8 + T lympho-
cytes in COPD [25, 26]. Another study also showed a trend 
towards increased proportions of IL-4 producing CD8 + T 
lymphocytes in COPD, but this was not significant [23]. On 
the other hand, Barceló et al. [29] found no difference in 
cytokine expression by circulating CD8 + T lymphocytes in 
COPD or controls whereas Barcyzk et al. [30] reported that 
the number of IL-4 producing CD8 + T lymphocytes was 
lower in the peripheral blood than in BAL.
Two studies calculated the Tc1/Tc2 ratio in participant 
samples: Shirai et al. [26] reported no difference in the ratio 
of IFN-g producing/IL-4-producing CD8 + T lymphocytes 
between COPD subjects and controls following analysis of 
peripheral blood. Conversely, Yu et al. [28] reported a sig-
nificantly higher Tc1/Tc2 ratio in both BAL and peripheral 
blood COPD samples. They also showed that a dominant 
Tc1 phenotype is associated with decreased lung function.
Finally, of the three studies which investigated the Tc17 
phenotype of CD8 + T lymphocytes in COPD, two studies 
utilised peripheral blood [23, 24] whereas one study sampled 
bronchial mucosa [22]. One of the peripheral blood studies 
[23] found no difference in the proportion of IL-17A and 
IL-17F producing CD8 + T lymphocytes in the circulation 
of COPD and control samples. On the contrary in the lung, 
Chang et al. [22] confirmed by immunofluorescence and 
reverse transcription PCR that bronchial CD8 + T lympho-
cytes from COPD subjects expressed IL-17A and IL-17F. 
Further investigation showed that CD8 + T lymphocytes 
were the principal IL-17A and IL-17F producing cells. Simi-
larly, analysis of peripheral blood by Xu et al. [24] showed 
that a significantly higher percentage of CD8 + T lympho-
cytes were of the Tc17 phenotype in COPD.
Cytotoxic function of CD8 + T lymphocytes in COPD
Ten studies investigated the cytotoxic function of CD8 + T 
lymphocytes in COPD [19–21, 33–39]. All included human 
participants and one study also used a mouse model [39] 
(further details are given in Online Resource 5). Analysis of 
human lung tissue was undertaken in four studies [20, 33, 
34, 38], peripheral blood in a different four studies [21, 36, 
37, 39] and samples of induced sputum [19] and epithelial 
lining fluid [35] were obtained in one study each.
Seven studies investigated the expression cytotoxic 
mediators by CD8 + T lymphocytes, of which six showed 
increased expression of granzyme and/or perforin in COPD 
[19, 20, 33–35, 39] whereas one reported decreased expres-
sion [21]. All three studies which analysed human lung tis-
sue found a significant association [20, 33, 34]. Analysis 
of induced sputum by Urbanowicz et al. [19] (see Table 2) 
showed increased expression of both perforin and granzyme 
B on CD8 + T lymphocytes from COPD. Furthermore, Shi-
ratuschi et al. [35] reported increased perforin in the central 
and peripheral airways of COPD following analysis of epi-
thelial lining fluid.
Of the two studies which sampled peripheral blood, one 
observed significantly lower expression of perforin and gran-
zyme B by CD8 + T lymphocytes in COPD compared to 
controls [21] (see Table 2). Hodge et al. [39] on the other 
hand showed increased numbers of CD8/CD28null cells in 
COPD and that these cells express significantly more gran-
zyme B and perforin than CD8/CD28 + T cells. Using a 
mouse model they showed that cigarette smoke exposure 
induced a significant increase in cytotoxic CD8/CD28null T 
lymphocytes in BAL and a trend towards an increase in lung 
tissue and peripheral blood.
Three studies evaluated the Fas/FasL pathway of cyto-
toxicity on CD8 + T lymphocytes. Two studies [36, 37] 
examined peripheral blood and showed increased expres-
sion of Fas (CD95) on circulating CD8 + T lymphocytes 
from COPD samples compared to smoker and non- smoker 
controls. One study [36] also showed that the proportion 
of CD8 + /Fas + T lymphocytes was associated with both 
reduced lung function and hypoxaemia. On the contrary in 
the lung, Freeman et al. [20] (see Table 2) found no asso-
ciation between lung function and the expression of FasL 
mRNA transcripts by lung CD8 + T lymphocytes.
Expression of PD-1, a member of the CD28 family of 
TCR molecules which is associated with a loss of cytotoxic 
function, was shown in one study to be increased on CD8 + T 
lymphocytes from COPD lung samples [38].
Other effector functions of CD8 + T lymphocytes 
in COPD
Five studies investigated other effector functions of CD8 + T 
lymphocytes in COPD. Four were mouse models [40–43] 
and one human [44]. Lung tissue was sampled in all four 
mouse models, three of which also examined BAL [41–43], 
whereas lung tissue, BAL and peripheral blood were 
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sampled in the human study (further details are given in 
Online Resource 6).
Dysregulation of the CD8 + T cell receptor (TCR) was 
found in two studies [40, 44] and the indirect effects of 
CD8 + T lymphocytes in the inflammatory process of COPD 
were shown in three murine models [41–43].
Role of CD8 + T lymphocytes in acute exacerbations 
of COPD
There were four papers identified which highlighted the role 
of CD8 + T lymphocytes in acute exacerbations of COPD 
(AECOPD) [45–48] (further details are given in Online 
Resource 7). Two studies which analysed peripheral blood 
had contrasting conclusions. When comparing the same sub-
jects at stable condition and at AECOPD, Freeman et al. [46] 
showed that CD8 + T lymphocytes decreased significantly 
in AECOPD and then increased back to a constant level 
at stable condition. They also concluded that the decline 
in CD8 + T cell frequency could be a potential marker of 
AECOPD since it preceded the onset of symptoms. Con-
versely, Chen et al. [45] compared three subject groups and 
highlighted that the percentage of CD8 + T lymphocytes in 
the peripheral blood was significantly greater in AECOPD 
than in stable COPD and non-smoking control samples.
There was overall agreement that the percentage of 
CD8 + T lymphocytes increased in the lungs of patients at 
onset of AECOPD. This was reported by two studies, both 
of which took induced sputum samples at the initial onset 
of exacerbation and then again after a follow-up of 8 or 
16 weeks [47, 48].
Discussion
Evidence from this review indicates that CD8 + T lym-
phocytes are both increased in number and have increased 
functional activity in COPD and highlights some potential 
mechanisms by which they may elicit pathogenesis.
The evidence shows that that patients with COPD have 
increased numbers of CD8 + T lymphocytes in the lung. This 
was highlighted in 16 out of 17 studies following analysis of 
lung tissue, BAL, induced sputum or bronchial mucosa. The 
same conclusion was not reached for the circulation where 7 
of the 14 studies found no difference, 5 showed an increase 
and 2 found a decrease in the number of cells in the periph-
eral blood of patients with COPD compared to controls. 
Systemic inflammation is present to some extent in COPD 
so it is interesting that the findings are so inconclusive. Per-
haps the CD8 + T lymphocytes migrate from the blood to 
the lungs during COPD or perhaps they spill out from the 
lungs into the blood [49] or combination of the two. Most 
likely however is that the inconsistency could be attributed 
to variability between studies: for instance, the control par-
ticipants were different in different studies, meaning that 
some COPD groups were compared to smokers whilst others 
were compared to healthy non-smokers.
Some studies showed a smoking related increase in 
CD8 + T lymphocytes however others did not. This suggests 
that the increased presence of these cells is most closely 
related to disease, not simply in response to cigarette smoke. 
The evidence also suggests that the number of cells in the 
lung is associated with disease severity. However, not all 
studies investigated the association between cell frequency 
and cigarette smoking and/or disease severity and therefore 
evidence is insufficient to reach a firm conclusion.
In addition to a greater quantity of cells, there was evi-
dence showing increased activation of CD8 + T lymphocytes 
in the lungs in COPD. The only study [14] which found no 
difference in activation had the smallest sample size in the 
review with only ten subjects, therefore making it less gen-
eralisable to the COPD population. In two studies, increased 
activation of lung CD8 + T lymphocytes was shown to be 
smoking-independent, raising the question as to what stimu-
lus these cells are responding to. Activation occurs following 
recognition and binding to antigen peptides but is also medi-
ated by cytokines such as IL-12 and IL-18 [50].
Upregulation of chemokine receptors on CD8 + T lym-
phocytes was also shown in COPD. CXCR3 is highly 
expressed on effector T cells following activation by ligands 
such as IP-10 [51]. CD8 + T lymphocytes themselves pro-
mote production of IP-10 via IFN-g [52]. IP-10 then recruits 
more CXCR3 + CD8 + T lymphocytes to the lung where they 
exert their inflammatory and destructive effects whilst con-
tinuing to attract more cells.
Effector CD8 + T lymphocytes differentiate into subpopu-
lations which can be discriminated by cytokine profile. Nine 
of eleven studies found a higher proportion of pro-inflam-
matory Tc1 cells in COPD. The two which did not reach 
this consensus were the oldest and therefore consistency in 
the recent findings increases confidence in this conclusion.
Likewise, conclusive findings from three mouse models 
showed significantly reduced alveolar destruction in the 
absence of CD8 + T lymphocytes, further suggesting their 
effects involve mediating emphysema-like changes. Animal 
models however are not truly representative of human dis-
ease and so the extent and means in which CD8 + T lympho-
cytes induce alveolar destruction in human tissue requires 
further investigation.
It was found consistently in five studies that in patients 
with COPD, CD8 + T lymphocytes have elevated expression 
of granzymes and/or perforin in the lung, following analy-
sis of lung tissue, epithelial lining fluid or induced sputum. 
Expression of granzyme B has been correlated with apoptosis 
of bronchial epithelial cells [53]. Therefore, it is plausible that 
increased expression of cytotoxic mediators by the already 
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increased number of CD8 + T lymphocytes contributes to 
lysis of structural cells in the lung, which is a principal char-
acteristic of emphysema. Nevertheless, CD8 + T lymphocytes 
may not be the only source of cytotoxic proteins. Two of the 
three studies which sampled lung tissue also noted staining of 
granzyme B on resident lung cells and innate immune cells, 
therefore suggesting these cells are not solely responsible for 
direct cell lysis.
In addition, there was evidence of increased Tc2 cells in 
COPD in 2/2 studies which examined BAL and 2/5 studies of 
the peripheral blood. Tc2 cells express IL-4 and IL-13 which 
promote immunoglobulin production by B lymphocytes [54]. 
Therefore, a possible consequence of increased Tc2 cells 
is greater antibody production. Tc2 cells have been associ-
ated with autoimmune diseases such as rheumatoid arthritis 
[55] so it is not out of the question that antibody production 
against self-antigens might contribute to the persistent inflam-
matory response in COPD. There is also literature describing 
increased autoantibodies in COPD [56], but the autoimmune 
function of CD8 + T lymphocytes specifically is yet to be 
explored.
AECOPD is a common cause of hospitalisation so a bet-
ter understanding of the immune response could provide 
insight for diagnostic and pharmacological targets. The role 
of CD8 + T lymphocytes in AECOPD was insufficiently 
explored but showed some promise. The number of CD8 + T 
lymphocytes in the lung, the majority of which were Tc2, was 
increased at AECOPD. This is unsurprising since AECOPD 
are associated with infection and so an enhanced immune 
response would be expected [57]. One cohort study which 
analysed peripheral blood found a decrease in CD8 + T lym-
phocytes in the circulation at AECOPD which then increased 
to a constant level at stable condition [46]. This may reflect 
cell extravasation out of the blood to fight infection in the lung. 
Interestingly, the decline in CD8 + T lymphocytes preceded 
the onset of symptoms, therefore highlighting these cells as 
a potential biomarker for AECOPD. Further investigations 
would be required to confirm this, but since diagnosis is based 
mainly on symptoms, there is demand for a clinical biomarker, 
making this a potentially exciting concept.
There are a number of unavoidable limitations associated 
with this systematic review: these are detailed in the Supple-
mentary Information. Briefly, differences between studies in 
terms of design (e.g., cross-sectional versus longitudinal), 
patient definition (e.g., current and ex-smokers), human ver-
sus animal studies, and heterogeneity in outcomes measured 
must be acknowledged.
Conclusion
This review confirms that the number of CD8 + T lympho-
cytes is increased in the lungs of patients with COPD. It 
also highlights the increased capacity of these cells to exert 
effector functions; namely secretion of pro-inflammatory 
cytokines and expression of cytotoxic proteins, and goes on 
to outline several potential mechanisms for their role in dis-
ease pathogenesis. The lack of evidence in some areas made 
it impossible to draw firm conclusions at this stage, but also 
identified some promising areas for further investigation.
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